Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor

Osteoarthritis and Cartilage

Volumn 10, Issue 10, 2002, Pages 785-791

  Janusz, M J ^a   Bendele, A M ^b   Brown, K K ^a   Taiwo, Y O ^a   Hsieh, L ^a   Heitmeyer, S A ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b BolderPATH   (United States)

Author keywords

Matrix metalloproteinase inhibitor; Meniscal tear model of OA; Rats

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HISTOPATHOLOGY; IMAGE ANALYSIS; IN VITRO STUDY; INHIBITION KINETICS; KNEE LIGAMENT; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; MALE; MEDICAL ASSESSMENT; MICROSCOPY; NONHUMAN; OSTEOPHYTE; PRIORITY JOURNAL; RAT; SURGICAL INJURY; SURGICAL TECHNIQUE; TIME; TREATMENT OUTCOME;

EID: 0036793151     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1053/joca.2002.0823     Document Type: Article

References (39)

1. Pond MJ, Nuki G. Experimentally-induced osteoarthritis in the dog. Ann Rheum Dis 1973;32:387-8.
2. Little C, Smith S, Ghosh P, Bellenger C. Histomorphological and immunohistochemical evaluation of joint changes in a model of osteoarthritis induced by lateral menisectomy in sheep. J Rheumatol 1997;24: 2199-209.
3. Moskowitz RW, Davis W, Sammaraco J, Martens M, Baker J, Mayor M, et al. Experimentally induced degenerative joint lesions following partial menisectomy in the rabbit. Arthritis Rheum 1973;16:397-405.
4. Bendele AM, White SL. Early histopathologic and ultrastructural alterations in femerotibial joints of partial medial menisectomized guinea pigs. Vet Pathol 1987;24:436-43.
5. Bendele AM. Progressive chronic osteoarthritis in femerotibial joints of partial medial menisectomized guinea pigs. Vet Pathol 1987;24:444-8.
6. Bendele AM, McComb J, Gould T, McAbee T, Sennello G, Chipala E, et al. Animal models of arthritis: Relevance to human disease. Toxicol Path 1999; 27:134-42.
7. Stoop R, Buma P, van der Kraan PM, Hollander AP, Billinghurst RC, Meijers THM, et al. Type II collagen degradation in articular cartilage fibrillation after anterior cruciate ligament transection in rats. Osteoarthritis Cart 2001;9:308-15.
8. Pelletier JP, Martel-Pelletier J, Altman RD, Ghandur-Mnaymneh L, Howell DS, Woessner JF. Collagenolytic activity and collagen matrix breakdown of articular cartilage in the Pond Nuki dog model of osteoarthritis. Arthritis Rheum 1983;26:866-74.
9. Pelletier JP, Faure MP, DiBattista, Wilhelm S, Visco D, Martel-Pelletier J. Coordinate synthesis of stromelysin, interleukin-1, and oncogene proteins in experimental osteoarthritis: an immunohistochemical study. Am J Pathol 1993;142:95-105.
10. Janusz MJ, Hookfin EB, Heitmeyer EB, Woessner JF, Freemont AJ, Hoyland, et al. Moderation of iodoacetate induced-experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cart 2001;9:751-60.
11. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996;97:761-8.
12. Moldovan F, Pelletier JM, Hambor J, Cloutier JM, Pelletier JM. Collagenase-3 (matrix metalloproteinase 13) is preferentially localized in the deep later of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor b. Arthritis Rheum 1997;40:1653-61.
13. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
14. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
15. Smith GN Jr, Yu LP, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritis cartilage. J Rheumatol 1998;25:532-5.
16. Yu LP, Smith GN, Brandt KD, Myers SL, O'Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992;35:1150-9.
17. De Bri E, Lei W, Svensson O, Chowdhury M, Moak SA, Greenwald RA. Effect of an inhibitor of matrix metalloproteinases on spontaneous osteoarthritis in guinea pigs. Adv Dent Res 1998;12:82-5.
18. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomly KMK. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998;41:1639-44.
19. Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, et al. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J Med Chem 2001;44:2499-502.
20. Bendele AM, Hulman JF. Effects of body weight restriction on the development and progression of spontaneous osteoarthritis in guinea pigs. Arthritis Rheum 1991;34:1180-4.
21. Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, Taiwo YO, et al. Design and synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem 1999;42:4547-62.
22. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS 1992;296:263-6.
23. Dean DD, Martel-Pellitier J, Pellitier J-P, Howell HS, Woessner JF. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84: 678-85.
24. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changes. Arthritis Rheum 2001;44:585-94.
25. Mehraban F, Kuo S-Y, Riera H, Chang C, Moskowitz RW. Prostromelysin and procollagenase genes are differentially up-regulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. Arthritis Rheum 1994;37:1189-97.
26. Huebner JL, Otterness IG, Freund EM, Caterson B, Kraus VB. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum 1998;41:877-90.
27. Roos H, Adalberth T, Dahlberg L, Lohmander LS. Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age. Osteoarthritis Cart 1995;3:261-7.
28. Stoop R, Buma P, van der Kraan PM, Hollander AP, Billinghurst RC, Poole AR. Differences in type II collagen degradation between peripheral and central cartilage of rat stifle joints after cranial cruciate ligament transection. Arthritis Rheum 2000;43: 2121-31.
29. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobulin domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992;267:1008-14.
30. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992;267:19470-4.
31. Fosang AJ, Last K, Knauper, Neame PJ, Murphy G, Hardingham TE, et al. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993;295: 273-6.
32. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36: 1214-22.
33. 374 bond of the interglobular domain. J Clin Invest 1992;89:1512-16.
34. Arner EC, Hughes CE, Decicco CP, Caterson B, Tortorella MD. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cart 1998;6:214-28.
35. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins. Science 1999;284:1664-6.
36. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS-11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-50.
37. Chambers MG, Cox L, Chong L, Suri N, Cover P, Bayliss MT, et al. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum 2001;44:1455-65.
38. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum 1993;36:1709-17.
39. Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the n-terminal end of the triple helix. Biochem J 1998;331:727-32.